KRAS mutation in pancreatic cancer

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer

(2020) Louis Buscail et al.   Nature Reviews Gastroenterology & Hepatology

High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D

(2020) Malcolm J. W. Sim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

(2020) Vito Amodio et al.   Cancer Discovery

Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer

(2020) Pingping Hou et al.   Cancer Discovery

436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer

(2020) D.H. Ahn et al.   ANNALS OF ONCOLOGY

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors

(2019) Tamer A. Ahmed et al.   Cell Reports

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

(2019) David H. Peng et al.   Science Translational Medicine

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival

(2019) Chih-Shia Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular subtypes of pancreatic cancer

(2019) Eric A. Collisson et al.   Nature Reviews Gastroenterology & Hepatology

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

(2019) Conan G. Kinsey et al.   NATURE MEDICINE

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

(2019) Kirsten L. Bryant et al.   NATURE MEDICINE

Progress in targeting RAS with small molecule drugs

(2019) Frank McCormick   BIOCHEMICAL JOURNAL

KRASG12C inhibition produces a driver-limited state revealing collateral dependencies

(2019) Kevin Lou et al.   Science Signaling

Tissue-Specific Oncogenic Activity of KRASA146T

(2019) Emily J. Poulin et al.   Cancer Discovery

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

(2019) Talia Golan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

(2019) Miriam Molina-Arcas et al.   Science Translational Medicine

Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition

(2019) Meagan B. Ryan et al.   CLINICAL CANCER RESEARCH

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

(2019) G. Aaron Hobbs et al.   Cancer Discovery

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers

(2019) Rita Sulahian et al.   Cell Reports

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

(2018) Eric Van Cutsem et al.   INTERNATIONAL JOURNAL OF CANCER

Therapeutic developments in pancreatic cancer: current and future perspectives

(2018) John P. Neoptolemos et al.   Nature Reviews Gastroenterology & Hepatology

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

(2018) Hervé Tiriac et al.   Cancer Discovery

Differential Effector Engagement by Oncogenic KRAS

(2018) Tina L. Yuan et al.   Cell Reports

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

(2018) Sandra Misale et al.   CLINICAL CANCER RESEARCH

Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study

(2018) Vasilios Karavasilis et al.   Targeted Oncology

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

(2017) Sushrut Kamerkar et al.   NATURE

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

(2017) Chaoyang Sun et al.   Science Translational Medicine

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

(2017) Andrew M. Waters et al.   Cold Spring Harbor Perspectives in Medicine

Synthetic Lethal Vulnerabilities in KRAS -Mutant Cancers

(2017) Andrew J. Aguirre et al.   Cold Spring Harbor Perspectives in Medicine

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy

(2017) Vincent Chung et al.   JAMA Oncology

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

(2016) Jonathan M. L. Ostrem et al.   NATURE REVIEWS DRUG DISCOVERY

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer

(2016) H. Kitai et al.   Cancer Discovery

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma

(2016) Barbara Bournet et al.   Clinical and Translational Gastroenterology

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

(2015) S. Kordes et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling

(2015) Man-Tzu Wang et al.   CELL

Organoid Models of Human and Mouse Ductal Pancreatic Cancer

(2015) Sylvia F. Boj et al.   CELL

Pharmacogenomic agreement between two cancer cell line data sets

(2015) Nicolas Stransky et al.   NATURE

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

(2015) Agnieszka K. Witkiewicz et al.   Nature Communications

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

(2014) Diane D. Shao et al.   CELL

Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation

(2014) Jamie E. Chaft et al.   Clinical Lung Cancer

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Vertical inhibition of the MAPK pathway enhances therapeutic responses inNRAS-mutant melanoma

(2014) Vito W. Rebecca et al.   Pigment Cell & Melanoma Research

Development of siRNA Payloads to Target KRAS-Mutant Cancer

(2014) T. L. Yuan et al.   Cancer Discovery

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

(2013) Stefan Boeck et al.   JOURNAL OF GASTROENTEROLOGY

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway

(2013) Jaekyoung Son et al.   NATURE

Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival

(2013) Sang Hyun Shin et al.   PANCREAS

Mutant KRAS is a druggable target for pancreatic cancer

(2013) E. Zorde Khvalevsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas

(2013) Georgia Konstantinidou et al.   Cancer Discovery

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

What We Have Learned About Pancreatic Cancer From Mouse Models

(2012) Pedro A. Pérez–Mancera et al.   GASTROENTEROLOGY

Mutated Ras-Transfected, EBV-Transformed Lymphoblastoid Cell Lines as a Model Tumor Vaccine for Boosting T-Cell Responses Against Pancreatic Cancer: A Pilot Trial

(2012) Boris Kubuschok et al.   HUMAN GENE THERAPY

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

(2012) Meredith A. Collins et al.   JOURNAL OF CLINICAL INVESTIGATION

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

(2012) Andrew V. Biankin et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Frequencies and Prognostic Role of KRAS and BRAF Mutations in Patients With Localized Pancreatic and Ampullary Adenocarcinomas

(2012) Nicolai Aagaard Schultz et al.   PANCREAS

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Pancreatitis-Induced Inflammation Contributes to Pancreatic Cancer by Inhibiting Oncogene-Induced Senescence

(2011) Carmen Guerra et al.   CANCER CELL

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

(2011) György Bodoky et al.   INVESTIGATIONAL NEW DRUGS

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

(2011) S. T. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

(2010) Milind M Javle et al.   BMC CANCER

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

(2010) C. A. Pratilas et al.   CLINICAL CANCER RESEARCH

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

Molecular Basis of Colorectal Cancer

(2009) Sanford D. Markowitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

(2008) Kevin M Haigis et al.   NATURE GENETICS